Wells Fargo
ANTX icon

Wells Fargo’s AN2 Therapeutics ANTX Stock Holding History

Wells Fargo’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108K Buy
+22,389
New +$96.3K ﹤0.01% 5493
2024
Q2 		– Sell
-128
Closed -$416 – 6892
2024
Q1 		$416 Buy
128
+2
+2% +$22 ﹤0.01% 6319
2023
Q4 		$2.58K Buy
126
+64
+103% +$1.07K ﹤0.01% 6058
2023
Q3 		$997 Buy
62
+27
+77% +$306 ﹤0.01% 6202
2023
Q2 		$298 Sell
35
-1,931
-98% -$13.9K ﹤0.01% 6583
2023
Q1 		$19.4K Buy
+1,966
New +$21.9K ﹤0.01% 5650
2022
Q4 		– Sell
-27
Closed – – 7447
2022
Q3 		$0 Sell
27
-46
-63% -$536 ﹤0.01% 6616
2022
Q2 		$1K Buy
+73
New +$967 ﹤0.01% 6453

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Wells Fargo's ANTX Position: Q2 2026 in Review

Wells Fargo opened a new position in AN2 Therapeutics (ANTX) in Q2 2026: 22,389 shares worth $108K. The stake represents ﹤0.01% of the portfolio and ranks #5493 among its holdings. This is a return to the name: Wells Fargo previously reported a position in ANTX as recently as Q1 2024.

Wells Fargo first reported a position in ANTX in Q2 2022 and has held it in 8 quarters since. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Wells Fargo held 22,389 shares of AN2 Therapeutics worth $108K as of Q2 2026.
  • AN2 Therapeutics was a new Wells Fargo position in Q2 2026.
  • AN2 Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5493 holding.
  • Wells Fargo first reported a position in AN2 Therapeutics in Q2 2022 and has held it in 8 quarters since.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.